Briacell's phase 3 trial gets Nature Medicine spotlight

Executive Summary

• Briacell Therapeutics' Phase 3 Bria-IMT clinical trial for metastatic breast cancer was featured in Nature Medicine’s "Eleven clinical trials that will shape medicine in 2026" as a "clinical trial to watch."
• The company anticipates reporting top-line data as early as the first half (H1) of 2026.
• The pivotal Phase 3 study (Bria-ABC) is evaluating Bria-IMT plus an immune checkpoint inhibitor versus physician's choice in advanced metastatic breast cancer, with the goal of supporting full approval and marketing authorization.

Key Details

• Media Recognition: The trial was independently featured in Nature Medicine Year In Review, selected by leading researchers as a key trial for 2026.
• Trial Design: The study evaluates Bria-IMT (a cell-based immunotherapy) combined with an immune checkpoint inhibitor against physician's choice therapy.
• Inclusivity: The trial includes all breast cancer subtypes, patients with brain metastases, those unable to work but able to care for themselves, and patients who have received extensive prior treatments, including antibody-drug conjugates or checkpoint inhibitors.
• Comparator: The study utilizes a real-world comparator arm to enhance the meaningfulness of results for everyday clinical practice.
• Enrollment Status: The Phase 3 study has screened more than 230 patients and enrolled over 160 patients to date.
• Interim Analysis Trigger: Interim data will be analyzed once 144 patient events (deaths) occur.
• Primary Endpoint: Overall Survival (OS).
• Regulatory Status: The Bria-IMT combination regimen has been granted FDA Fast-Track designation.
• Strategic Goal: Positive results from this pivotal study could support full approval and marketing authorization of Bria-IMT for patients with metastatic breast cancer.

Notable Quotes

• Dr. Sara A. Hurvitz, MD, FACP (Smith Family Endowed Chair in Women's Health at Fred Hutchinson Cancer Center): "The BRIA-ABC trial is an exciting study focused on people living with metastatic breast cancer. Even though cancer care has come a long way, metastatic breast cancer is still rarely curable and only a small fraction of patients benefit long-term from current immunotherapy or targeted treatments. That is why this trial was designed -- to see if a new cell-based immunotherapy, called Bria-IMT, can actually improve outcomes for people who have already gone through many prior treatments."
• Dr. Sara A. Hurvitz: "What really sets BRIA-ABC apart is how inclusive it is. It welcomes individuals with all breast cancer subtypes, including patients who cannot work but are able to take care of themselves -- and those with brain metastases and people who have already had extensive prior treatments, even antibody-drug conjugates or checkpoint inhibitors. Plus, it uses a real-world comparator arm, making the results much more meaningful for everyday clinical practice."